Last reviewed · How we verify
Test-Bepotastine salicylate 9.64 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Test-Bepotastine salicylate 9.64 mg (Test-Bepotastine salicylate 9.64 mg) — Korea University Anam Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Test-Bepotastine salicylate 9.64 mg TARGET | Test-Bepotastine salicylate 9.64 mg | Korea University Anam Hospital | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Test-Bepotastine salicylate 9.64 mg CI watch — RSS
- Test-Bepotastine salicylate 9.64 mg CI watch — Atom
- Test-Bepotastine salicylate 9.64 mg CI watch — JSON
- Test-Bepotastine salicylate 9.64 mg alone — RSS
Cite this brief
Drug Landscape (2026). Test-Bepotastine salicylate 9.64 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/test-bepotastine-salicylate-9-64-mg. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab